2023 Literature Analysis

Registration Options

Activity Dates: 02/23/2023 - 11/30/2023

Sign in (or create a FREE account) to register or access your existing registrations

Target Audience

This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.

Content

The articles selected by AAPP Recertification Editorial Board for the Literature Analysis are based on a 7-year curriculum. This curriculum is developed using the Board of Pharmaceutical Specialties' Content Outline for the Psychiatric Pharmacy Specialty Certification Examination as a guideline. Since AAPP became the sole BCPP Recertification provider in 2008, the articles are chosen to cover the three content domains - Domain 1 - Person-Centered Care, Domain 2 - Translation of Evidence into Practice and Education, Domain 3 - Healthcare Policy, Advocacy, and Practice Management.

The Literature Analysis is self-study, online only, knowledge-based continuing pharmacy education (CPE) activity. The 2023 Literature Analysis product includes an article complimented by a 1 hour recorded webinar by Dr. Roger Sommi, PharmD, BCPP, FCPP, assisting you as the learner in making accurate interpretations of the article. You are encouraged to read the article first and then watch the webinar while keeping the article open for frequent referral back to sections as guided by Dr. Sommi. The Literature Analysis components consist of:

  • Electronic access to all required journal articles needed to prepare for the online assessment.
  • The webinar that accompanies article #1 as provided by Dr. Roger Sommi.
  • For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online AAPP recertification examination.
  • Access to the  AAPP testing center with exam submission due by or on November 30, 2023.
  • The opportunity to provide  AAPP feedback on the entire product.

Course Requirements

To satisfactorily complete the Literature Analysis and receive 10 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:

  1. Abide by a confidentiality and honesty statement requiring individual completion of the recertification education.
  2. Complete an online assessment on or before the deadline of November 30, 2023.
  3. Receive a passing score (78%) as determined by a panel of experts.
  4. Partial credit is not available for individual topics within the Literature Analysis programming; it is either all 10 hours of Literature Analysis programming credit or none.

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • Wait for the official review of exam questions within 4 weeks following the closing date.
  • Receive a passing grade (78%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

Learning Objectives

Article Number Topic Article and Learning Objectives
1

How to compare results of placebo-controlled trials across different medications

Article 1 on “Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression” is complimented by a 1 hour recorded webinar by Dr. Roger Sommi, PharmD, BCPP, assisting you as the learner in making accurate interpretations of the article. You are encouraged to read the article first and then watch the webinar while keeping the article open for frequent referral back to sections as guided by Dr. Sommi.

Cooper, M.C., Kilvert, H.S., Hodgkins, P. et al. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression. CNS Drugs 33, 1039–1052 (2019). https://doi.org/10.1007/s40263-019-00672-w

The Recertification Editorial Board generally avoids using industry-sponsored trials for our literature analysis product. This study compares data from Phase II and III brexanolone trials to published trials of pharmacotherapy for the same indication. Most studies of this type are completed by the manufacturer because individual patient data is needed for this type of comparison. As this article is accompanied by a webinar, potential areas of bias can be addressed.

  1. Describe statistical methods for comparing the relative effectiveness of medications in the absence of head-to-head clinical trial data.
  2. Identify features of and uses for indirect treatment comparisons.
  3. Describe the internal validity and generalizability of the design and outcomes of a study for treatment of postpartum depression which uses indirect treatment comparison methods to assess relative effectiveness.
2

Schizophrenia

Jürgens G, Andersen SE, Rasmussen HB, et al. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(12):e2027909. doi:10.1001/jamanetworkopen.2020.27909

  1. Explain the results of pharmacogenomic cytochrome P450 testing.
  2. Identify treatment and/or monitoring strategies guided by pharmacogenomic testing in patients with schizophrenia.
  3. Discuss the clinical utility, including potential limitations, of pharmacogenomic testing in patients with schizophrenia.
3

Suicide

Katz IR, Rogers MP, Lew R, et al. Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022;79(1):24–32. doi:10.1001/jamapsychiatry.2021.3170

  1. Identify patient-specific factors that determine appropriate candidates for lithium augmentation to reduce suicide-related events.
  2. Describe factors that may influence the effectiveness of lithium augmentation to reduce suicide-related events in patients with bipolar disorder or depression.
  3. Discuss potential risks and benefits of lithium augmentation to reduce suicide-related events in patients with bipolar disorder or depression.
4

Migraine Consensus Guideline

Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23. PMID: 34160823.

  1. Select appropriate acute and/or preventive treatment of migraine headaches based on patient specific factors.
  2. Identify patients who are appropriate candidates for recently approved migraine treatments.
  3. Describe important components of a comprehensive migraine treatment plan.
  4. Identify adverse effects and/or risks associated with newer migraine treatments.
5

Transition in Care

Gryglewicz, K., Peterson, A., Nam, E., Vance, M. M., Borntrager, L., & Karver, M. S. (2021). Caring transitions—A care coordination intervention to reduce suicide risk among youth discharged from inpatient psychiatric hospitalization. Crisis: The Journal of Crisis Intervention and Suicide Prevention. Advance online publication. https://doi.org/10.1027/0227-5910/a000795

  1. Identify elements of transitions of care for suicide risk reduction in youth after psychiatric hospitalization.
  2. Describe outcomes of transitions of care intervention in youth after psychiatric hospitalization.
  3. Select factors that affect service utilization in transitional mental healthcare after psychiatric hospitalization.
6

Depression in Epilepsy

Mula M, Brodie MJ, deToffol B, Guekht A, Hecimovic H, Kanemoto K, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63:316–334. https://doi.org/10.1111/epi.17140

  1. Describe safety concerns with treatment options for depression in patients with epilepsy. 
  2. Select a treatment for depression in patients with epilepsy.
  3. Identify potential drug interactions between psychiatric and antiseizure medications.
7

Anxiety Disorders

Jerome, L., Feduccia, A.A., Wang, J.B. et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237, 2485–2497 (2020). https://doi.org/10.1007/s00213-020-05548-2

  1. Describe the efficacy of MDMA in MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder (PTSD).
  2. Identify the potential benefits of MDMA-assisted psychotherapy in patients with PTSD.
  3. Identify potential harm and/or characteristics that increases the risks associated with MDMA-assisted psychotherapy for treatment of PTSD.
8

Buprenorphine Initiation and Dosing

Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict. 2021;30(4):305-15.

  1. Identify the risks and/or benefits of buprenorphine microinduction in patients with opioid use disorder (OUD).
  2. Describe clinical scenarios appropriate for buprenorphine microinduction over traditional induction.
  3. Select appropriate buprenorphine induction protocols based on patient characteristics.

Continuing Education Credit and Disclosures

Activity Dates: 02/23/2023 - 11/30/2023
ACPE Contact Hours: 10
ACPE Number: 0284-0000-23-002-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Literature Analysis product is an application-based program approved for 10 hours of ACPE credit. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.

Board Certified Psychiatric Pharmacists (BCPPs) may also receive 10 hours of BCPP Recertification Credit for the Literature Analysis upon successful completion of an online examination.

The American Association of Psychiatric Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). This course is part of a 10 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.

AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.